BCRX250117P13000
- 0.00
- 0.000.00%
BioCryst Pharmaceuticals Newsroom
BioCryst Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $12
BioCryst Pharma Analyst Ratings
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $15
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Announces Target Price $11
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $12
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $18
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
BioCryst Pharmaceuticals Price Target Maintained With a $14.00/Share by Needham
BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays
BioCryst Pharma Analyst Ratings
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $8 to $30
Piper Sandler Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $20
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $16
BioCryst Pharmaceuticals Price Target Raised to $7.00/Share From $6.00 by Barclays